Compare Capri Holdings Ltd (CPRI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Capri Holdings Ltd trades at $14.95 (market cap $1.67B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 6.1× Capri Holdings Ltd's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| CPRI | XBI | |
|---|---|---|
Market Cap | $1.67B | $10.11B |
Volume | 3,722,279 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $27.66 | $169.55 |
52-Week Low | $12.71 | $104.99 |
Typical Hold Time | 41 Days | 38 Days |
Enterprise Value | $2.95B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.68, up 1.66% today, with a bullish technical signal from moving averages. The stock has beaten EPS estimates in recent quarters, but faces fundamental headwinds with revenue declining to $4.44B in 2025 and a net loss of $1.18B. Analyst consensus is a $20.57 price target, with 44% buy ratings. Recent news highlights brand revitalization efforts and second-half growth expectations from management commentary at the Goldman Sachs conference.
The outlook balances low valuation multiples against operational challenges. Investment appeal lies in potential margin improvement and brand turnaround, but risks include sustained revenue weakness, high debt levels, and competitive pressures in the luxury sector. The stock's recovery hinges on execution of the Michael Kors reset and macroeconomic support for consumer discretionary spending.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
